Pathogenesis of prostate cancer: Lessons from basic research

Ochsner Journal

Volumn 8, Issue 4, 2008, Pages 213-218

  Velcheti, Vamsidhar ^a   Karnik, Satish ^a   Bardot, Stephen F ^a   Prakash, Om ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Adenocarcinoma; Androgen receptor; Hormone resistance; Prostate; Signaling pathways; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DASATINIB; FLUTAMIDE; GROWTH FACTOR; MEGESTEROL ACETATE; NILUTAMIDE; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; DISEASE COURSE; DNA BINDING; GENE AMPLIFICATION; GENE MUTATION; HORMONE RESISTANCE; HUMAN; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION;

EID: 58549091646     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin. 2008;58:71-96.
2. Walcott JL, Merry DE. Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm. 2002;65:127-147.
3. Casella R, Maduro MR, Lipshultz LI, Lamb DJ. Significance of the polyglutamine tract polymorphism in the androgen receptor. Urology. 2001;58:651-656.
4. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006;99:362-372.
5. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int. 2005;95:1320-1326.
6. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 2007;120:719-733.
7. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996;28:251-265.
8. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med. 2004;10:33-39.
9. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 1995;9:401-406.
10. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892-2898.
11. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol. 2000;164:1992-1995.
12. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60:944-949.
13. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
14. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001-3015.
15. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149:607-609.
16. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem. 2004;91:3-12.
17. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59:2511-2515.
18. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998;159:149-153.
19. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am. 1997;24:421-431.
20. Haapala K, Hyytinen ER, Roiha M, et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest. 2001;81:1647-1651.
21. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008;180:921-927.
22. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling partnerships in prostate cancer cells. Endocr Rel Cancer. 2008;15:841-849.
23. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-5478.
24. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006;27:1-22.
25. Festuccia C, Muzi P, Millimaggi D, et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Rel Cancer. 2005;12:983-998.
26. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol. 2004;130:604-614.
27. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497-505.
28. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702-2706.
29. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659-6666.
30. Aaronson DS, Muller M, Neves SR, et al. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocr. 2007;270:50-56.
31. Ohlson N, Bergh A, Stattin P, Wikstrom P. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate. 2007;67:32-40.
32. Liao Y, Abel U, Grobholz R, et al. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathol. 2005;36:1186-1196.
33. Lee JT, Lehmann BD, Terrian DM, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 2008;7:1745-1762.
34. Lee JT, Steelman LS, Chappell WH, McCubrey JA. Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle. 2008;7:631-636.
35. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59:4291-4296.
36. Goldenberg-Furmanov M, Stein I, Pikarsky E, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 2004;64:1058-1066.
37. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 2007;9:90-100.
38. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007;18:1765-1773.
39. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323-3333.
40. Sanchez P, Clement V, Ruiz i Altaba A. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res. 2005;65:2990-2992.
41. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:119-126.
42. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369-3373.
43. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.